Metirosine
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(2S)-2-amino- 3-(4-hydroxyphenyl)- 2-methylpropanoic acid
|
|
| Clinical data | |
| Trade names | Demser |
| AHFS/Drugs.com | Consumer Drug Information |
| Pharmacokinetic data | |
| Biological half-life | 3.4–3.7 hours |
| Identifiers | |
| CAS Number | 672-87-7  |
| ATC code | C02KB01 (WHO) |
| PubChem | CID 10123 |
| IUPHAR/BPS | 6956 |
| DrugBank | DB00765 |
| ChemSpider | 390103 |
| UNII | DOQ0J0TPF7 |
| KEGG | D00762 |
| ChEMBL | CHEMBL1200862  |
| Chemical data | |
| Formula | C10H13NO3 |
| Molar mass | 195.215 g/mol |
|
|
|
|
| (what is this?) (verify) |
|
Metirosine (INN and BAN; α-Methyltyrosine, Metyrosine USAN, AMPT) is an antihypertensive drug. It inhibits the enzyme tyrosine hydroxylase and, therefore, catecholamine synthesis, which, as a consequence, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body.
Clinical use[edit]
Metirosine has been used in the treatment of pheochromocytoma.[1] It is contra-indicated for the treatment of essential hypertension.
However it is now rarely used in medicine, its primary use being in scientific research to investigate the effects of catecholamine depletion on behaviour.[2]
See also[edit]
References[edit]
- ^ Green KN, Larsson SK, Beevers DG, Bevan PG, Hayes B (August 1982). "Alpha-methyltyrosine in the management of phaeochromocytoma". Thorax. 37 (8): 632–3. doi:10.1136/thx.37.8.632. PMC 459390
. PMID 7179194. - ^ O'Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, Page ME, Lucki I. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology (Berlin). 2007 Jun;192(3):357-71. PMID 17318507
